REGN2810

Phase 3Small molecule

Regeneron

REGN2810 is one of 128 small molecule programs targeting Choroidal Neovascularization. It is currently in Phase 3.

Indications

Total Trials

Active Trials

127

Competitors

Pipeline

Status by Indication[3][1]

Indication

Choroidal NeovascularizationActive, not recruiting

Lung CancerActive, not recruiting

Non-Small Cell Lung CancerActive, not recruiting

MelanomaActive, not recruiting

Prostate CancerActive, not recruiting

Choroidal NeovascularizationPhase 2

Active, not recruiting

Lung CancerPhase 3

Active, not recruiting

Non-Small Cell Lung CancerPreclinical

Active, not recruiting

MelanomaPhase 1

Active, not recruiting

Prostate CancerPhase 2

Active, not recruiting

Competition

Competitive Landscape

1639 competitors in Non-Small Cell Lung Cancer

#DrugCompanyPhaseTrials

REGN2810

Regeneron

Phase 3

1 2

Yervoy

Bristol-Myers Squibb

Preclinical

31 3

Gemzar

GGynecologic Oncology Group

Preclinical

72 4

PORTRAZZA

Eli Lilly

Preclinical

8 5

Imjudo

AstraZeneca

Preclinical

5 6

Gilotrif

Boehringer Ingelheim

Preclinical

12 7

Ofev

Boehringer Ingelheim

Preclinical

7 8

Remeron

OOrganon and Co

Preclinical

1 9

Tyrosine Kinase Inhibitor

Pfizer

Preclinical

2 10

Aqupla

Jiangsu Simcere Pharmaceutical Co., Ltd.

Preclinical

—

Ranked by pipeline maturity and clinical activity. Current drug highlighted in teal.

Timeline

Expected Milestones

Q2 2027

Active, not recruiting

Non-Small Cell Lung Cancer

NCT06269133

Q2 2028

Phase 2Active, not recruiting

Prostate Cancer

NCT03951831

Clinical

Trials by Indication[1]

Non-Small Cell Lung Cancer1 trial

Evaluation of Cemiplimab in Combination With Platinum-Doublet Chemotherapy in First-Line (1L) Treatment of Advanced Non-Small Cell Lung Cancer (NSCLC) in Adult United States (US) Patients

Active, not recruiting· Regeneron logo

Regeneron··NCT06269133·1,000 enrolled

Head and Neck Cancer1 trial

An Exploratory Tumor Biopsy-driven Study to Understand the Relationship Between Biomarkers and Clinical Response in Patients With Head and Neck Cancer Receiving REGN2810 (Anti-PD-1)

Completed· Regeneron logo

Regeneron·Phase 1·NCT03198130·33 enrolled

PD-11 trial

Companion Study for Patients Who Completed Participation in a REGN2810 (Anti-PD-1) Clinical Study

Withdrawn· Regeneron logo

Regeneron·Phase 1·NCT02520245

Prostate Cancer1 trial

REGN2810 Followed by Chemoimmunotherapy for Newly Metastatic Hormone-sensitive Prostate Cancer

Active, not recruiting·MMark Stein·Phase 2·NCT03951831·26 enrolled

Lung Cancer1 trial

Combinations of Cemiplimab (Anti-PD-1 Antibody) and Platinum-based Doublet Chemotherapy in Patients With Lung Cancer

Completed· Regeneron logo

Regeneron·Phase 3·NCT03409614·790 enrolled

1 more indication

Melanoma1 trial

An Exploratory Tumor Biopsy-driven Study to Understand the Relationship Between Biomarkers and Clinical Response in Melanoma Patients Receiving REGN2810 (Anti-PD-1)

Completed· Regeneron logo

Regeneron·Phase 1·NCT03002376·47 enrolled

Sources

References

[1]
ClinicalTrials.gov — 6 trial records for REGN2810. U.S. National Library of Medicine, National Institutes of Health.
[2]
ChEMBL — REGN2810 compound record. European Bioinformatics Institute (EMBL-EBI).
[3]
Open Targets Platform — Drug–disease associations for REGN2810. EMBL-EBI & Wellcome Sanger Institute.
[4]
SEC EDGAR — Regeneron company filings. U.S. Securities and Exchange Commission.

Details

Drug Info

Quick Facts

Modality: Small molecule[2]
Highest Phase: Phase 3[1]
Company: Regeneron

REGN2810

Status by Indication[3][1]

Competitive Landscape

Expected Milestones

Q2 2027

Q2 2028

Trials by Indication[1]

Non-Small Cell Lung Cancer1 trial

Head and Neck Cancer1 trial

PD-11 trial

Prostate Cancer1 trial

Lung Cancer1 trial

Melanoma1 trial

References

Drug Info

Quick Facts

Related News